Vimta Labs Limited - Asset Resilience Ratio
Vimta Labs Limited (VIMTALABS) has an Asset Resilience Ratio of 15.99% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Vimta Labs Limited carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Vimta Labs Limited's Asset Resilience Ratio has changed over time. See net assets of Vimta Labs Limited for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vimta Labs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Vimta Labs Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs545.38 Million | 10.53% |
| Short-term Investments | Rs283.23 Million | 5.47% |
| Total Liquid Assets | Rs828.61 Million | 15.99% |
Asset Resilience Insights
- Good Liquidity Position: Vimta Labs Limited maintains a healthy 15.99% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Vimta Labs Limited Industry Peers by Asset Resilience Ratio
Compare Vimta Labs Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Vimta Labs Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Vimta Labs Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 3.62% | Rs168.85 Million ≈ $1.83 Million |
Rs4.67 Billion ≈ $50.45 Million |
+0.58pp |
| 2024-03-31 | 3.04% | Rs121.60 Million ≈ $1.32 Million |
Rs4.00 Billion ≈ $43.26 Million |
+0.54pp |
| 2023-03-31 | 2.50% | Rs90.73 Million ≈ $981.21K |
Rs3.62 Billion ≈ $39.18 Million |
+2.37pp |
| 2022-03-31 | 0.13% | Rs4.06 Million ≈ $43.91K |
Rs3.07 Billion ≈ $33.22 Million |
-0.01pp |
| 2021-03-31 | 0.14% | Rs3.92 Million ≈ $42.39K |
Rs2.74 Billion ≈ $29.67 Million |
-0.24pp |
| 2020-03-31 | 0.38% | Rs9.32 Million ≈ $100.79K |
Rs2.46 Billion ≈ $26.58 Million |
+0.18pp |
| 2019-03-31 | 0.20% | Rs4.70 Million ≈ $50.83K |
Rs2.37 Billion ≈ $25.68 Million |
-0.85pp |
| 2018-03-31 | 1.05% | Rs24.39 Million ≈ $263.77K |
Rs2.32 Billion ≈ $25.12 Million |
+0.58pp |
| 2017-03-31 | 0.47% | Rs10.45 Million ≈ $113.01K |
Rs2.22 Billion ≈ $23.97 Million |
+0.38pp |
| 2011-03-31 | 0.09% | Rs1.58 Million ≈ $17.09K |
Rs1.77 Billion ≈ $19.09 Million |
-12.57pp |
| 2007-03-31 | 12.66% | Rs220.22 Million ≈ $2.38 Million |
Rs1.74 Billion ≈ $18.81 Million |
-28.47pp |
| 2006-03-31 | 41.13% | Rs702.53 Million ≈ $7.60 Million |
Rs1.71 Billion ≈ $18.47 Million |
-- |
About Vimta Labs Limited
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract researc… Read more